Submit Content
Sponsored in Part By
Sponsored

Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

Submitted by
Sep. 25, 2018
0

This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death. No new safety concerns were raised.

View Source Article
0 comments

Leave a Reply

Source

The New England Journal of Medicine

Authors

Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeño, Corinne Faivre-Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu for the PACIFIC Investigators

Tags

Lung - Cancer Thoracic Lung Cancer Lung Cancer - Other Lung Cancer - Chemotherapy Lung Cancer - Multimodality Therapy

Log In

New to CTSNet? Sign Up

Forgot Password